VCYT

Congress Trades

Actor	Trade Size	Last Transaction	Amount Range	Price	Current Price
Gilbert CisnerosDemocrat $8.0k218.5 shares BuyFeb 18, 2026 $1k-$15k $36.61 --

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Stapley MarcDirector, Officer: Chief Executive Officer $22M440.5k shares SellJun 4, 2026 $6.9M138.1k shares $50.12 --
Stapley MarcDirector, Officer: Chief Executive Officer $0138.1k shares Grant / ExerciseJun 4, 2026 $5.1M138.1k shares $36.60 --
Leite JohnGlobal Chief Commercial Off $6.6M132.3k shares SellJun 4, 2026 $699.7K14k shares $50.07 --
Chambers RebeccaChief Financial Officer $8.7M173.3k shares SellJun 4, 2026 $98.2K2k shares $50.09 --
McGuire AnnieEVP, General Counsel $6.9M137.2k shares SellJun 4, 2026 $89.0K1.8k shares $50.12 --
Chambers RebeccaChief Financial Officer $8.6M175.2k shares SellJun 4, 2026 $78.9K1.6k shares $49.28 --

News

zacks.comHere's Why Veracyte (VCYT) is a Strong Growth Stockzacks.comJun 9

fool.comState Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?fool.comJun 4

zacks.comWhy Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?zacks.comJun 4

seekingalpha.comVeracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcriptseekingalpha.comJun 1

gurufocus.comVeracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.gurufocus.comJun 1

Trade VCYT

About Veracyte, Inc.

Veracyte, Inc. operates as a global diagnostics company, specializing in the development and commercialization of advanced genomic tests. The company's product portfolio encompasses several key diagnostic solutions: The Afirma Genomic Sequencing Classifier and Xpression Atlas, which help patients with indeterminate thyroid nodule results avoid unnecessary surgical procedures by identifying benign cases. Decipher Prostate Biopsy and Radical Prostatectomy tests for the diagnosis of prostate cancer. The Prosigna Breast Cancer Assay, used for breast cancer diagnosis. Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test, both designed for lung cancer diagnosis. The Envisia Genomic Classifier, which aids in diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. The Immunoscore Colon Cancer test for colon cancer detection. Veracyte is also actively engaged in developing future diagnostic tools, such as the Percepta Genomic Atlas to inform lung cancer treatment decisions; an Envisia Classifier that leverages the nCounter analysis system; and the LymphMark test for precise lymphoma subtyping. The company maintains strategic technology licensing and collaborative agreements with entities including Johnson & Johnson, Acerta Pharma, and CareDx. Incorporated in 2006, the organization was initially known as Calderome, Inc., before officially changing its name to Veracyte, Inc. in March 2008. Its corporate headquarters are situated in South San Francisco, California.

CEO: Marc A. Stapley
IPO Date: Oct 30, 2013

Market Data

Open: $49.45
High: $49.75
Low: $47.96
Volume: 1.1M
52W High: $50.71
52W Low: $22.61

Valuation

Market Cap: $3.9B
Enterprise Value: $3.7B

Financials

Free Cash Flow: $127M
Revenue: $517M
Net Income: $66M
Cash: $363M
Debt: $40M

Events

EarningsAug 5

EPS est. 0.44